Pharmacoeconomic evaluation of the effectiveness of therapy for metastatic colorectal cancer

QR Code

Pharmacoeconomic evaluation of the effectiveness of therapy for metastatic colorectal cancer

Objective: to perform a pharmacoeconomic evaluation of the effectiveness of therapies for metastatic colorectal cancer (mCRC) based on real practical data on medical help for patients with this disease.Material and methods. The authors performed a comparative cost-effectiveness analysis and the calc...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yu. Yu. Petukhova, E. V. Eliseeva, M. V. Volkov, O. N. Li, A. G. Petukhova
Format:	Article
Language:	Russian
Published:	IRBIS LLC 2021-10-01
Series:	Фармакоэкономика
Subjects:	colorectal cancer chemotherapy targeted therapy cost-effectiveness ratio
Online Access:	https://www.pharmacoeconomics.ru/jour/article/view/546
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Modern strategy of metastatic colorectal cancer treatment (literature review)
by: O. I. Kit, et al.
Published: (2024-09-01)

Efficacy and safety of immunotherapy combined with targeted therapy and chemotherapy in third-line treatment of microsatellite stable metastatic colorectal cancer
by: ZHAO Wensi, et al.
Published: (2025-07-01)

Multimodal therapy for metastatic colorectal cancer: a case of complete clinical and radiological response of liver metastases
by: A. Yu. Dobrodeev, et al.
Published: (2024-03-01)

CLINICAL AND ECONOMIC JUSTIFICATION OF SOFTWARE SCREENING PERFORMANCE OF COLORECTAL CANCER AT THE REGION LEVEL
by: Yu. Yu. Petukhova, et al.
Published: (2021-12-01)

Comprehensive review of the resistance mechanisms of colorectal cancer classified by therapy type
by: Janice M. Oh, et al.
Published: (2025-07-01)

Regional clinical and economic model of colorectal cancer screening
by: P. V. Nesterov, et al.
Published: (2020-09-01)

The impact of different treatments on thromboelastography and other conventional parameters in patients with colorectal cancer
by: Wenqin Ren, et al.
Published: (2024-12-01)

The role of KRAS and NRAS mutation detection in determining the therapy strategy for colorectal cancer
by: A. N. Toropovskiy, et al.
Published: (2022-11-01)

Issue of colorectal cancer at the beginning of XXI century: achievements and prospects
by: O. I. Kit
Published: (2013-07-01)

Cost-effectiveness analysis of capecitabine versus active monitoring in stable or responding metastatic colorectal cancer after 16 weeks of first-line therapy
by: Tong Liu, et al.
Published: (2025-12-01)

Colonoscopy, Biomarkers, and Targeted Therapy in Colorectal Cancer
by: Rustam Effendi-YS
Published: (2022-09-01)

EGFR inhibitors in the treatment of colorectal cancer
by: M. В. Zabelin, et al.
Published: (2018-09-01)

Metastatic Colon Cancer in a Pregnant Woman: A Case Report
by: Tsvetomir Ivanov, et al.
Published: (2019-01-01)

METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY
by: N. A. Avxentyev, et al.
Published: (2016-09-01)

Potential of using transcriptome sequencing data in choosing therapy for patients with colorectal cancer
by: S. V. Apalko, et al.
Published: (2025-01-01)

Main aspects of personalized approach to the treatment of patients with chemotherapy resistant metastatic colorectal cancer
by: O. Yu. Stukalova, et al.
Published: (2024-12-01)

Ongoing 5-year+ survival after multiple metastasectomies, followed by CAPOX plus bevacizumab, for metastatic colorectal cancer
by: Kozue Matsuishi, et al.
Published: (2020-06-01)

Oxaliplatin combined with capecitabine therapy and comprehensive nursing in advanced colorectal cancer patients
by: Dan Kuang, et al.
Published: (2025-07-01)

Cost-effectiveness analysis of cadonilimab plus bevacizumab and chemotherapy for persistent, recurrent, or metastatic cervical cancer
by: Kaixuan Wang, et al.
Published: (2025-06-01)

Pharmacoeconomic Analysis of Therapy with Generic Statin Drugs in Patients with High and Very High Cardiovascular Risk (According to the Study PRIORITY)
by: S. Yu. Martsevich, et al.
Published: (2020-11-01)

Triplet Regimen of Metronomic Capecitabine Plus Antiangiogenic Drug and PD‐1 Inhibitor as Later‐Line Salvage Treatment for Patients With MSS/pMMR Metastatic Colorectal Cancer: A Retrospective Study
by: Qiong Yang, et al.
Published: (2025-07-01)

Mutational profile of KRAS-positive colorectal cancer
by: E. N. Telysheva, et al.
Published: (2022-03-01)

Short-term outcomes of neoadjuvant chemotherapy in colorectal cancer patients with isolated liver metastasis
by: A. Yu. Dobrodeev, et al.
Published: (2023-01-01)

Systemic adjuvant and perioperative chemotherapy following curative-intent liver metastasectomy in colorectal cancer—is it justified?
by: R.D. Peixoto, et al.
Published: (2025-09-01)

DISSEMINATED OVARIAN CANCER: MODERN APPROACH TO DRUG THERAPY (REVIEW OF PUBLISHED LITERATURE)
by: S. V. Molchanov, et al.
Published: (2016-02-01)

Transarterial Chemoembolization of Metastatic Liver Lesions in Patients with Colorectal Cancer
by: O. Yu. Stukalova, et al.
Published: (2019-12-01)

Single nucleotide polymorphisms: impact on susceptibility to chemotherapy in patients with colorectal cancer
by: M. Angeles Vaz-Salgado, et al.
Published: (2024-12-01)

Nivolumab monotherapy in metastatic colorectal cancer: current approaches to response evaluation
by: N. N. Babyshkina, et al.
Published: (2022-11-01)

Evolution of drug therapy in patients with resectable gastric and esophageal‑gastric junction cancer
by: M. V. Sedova, et al.
Published: (2023-06-01)

The Interplay Between the Gut Microbiota and Colorectal Cancer: A Review of the Literature
by: Marco Cintoni, et al.
Published: (2025-06-01)

Improvement of long-term treatment results in oligometastatic colorectal cancer patients by using a combined approach
by: E. O. Kalmykova, et al.
Published: (2024-12-01)

SHORT-TERM RESULTS OF SIMULTANEOUS SURGERIES AT METASTATIC COLORECTAL CANCER
by: A. S. Zagaynov, et al.
Published: (2017-02-01)

Pharmacoeconomic evaluation of first-line combination therapy with immunotherapy drugs and platinum-containing chemotherapy in adult patients with metastatic non-squamous non-small cell lung cancer
by: S. К. Zyryanov, et al.
Published: (2024-05-01)

Prognostic Factors Influencing the Efficacy of Regorafenib in the Treatment of Metastatic Colorectal Cancer
by: Nadiye SEVER, et al.
Published: (2025-06-01)

Contrast Enhanced Ultrasound in the Diagnosis and Evaluation of the Efficiency of Chemotherapy in Patients with Colorectal Liver Metastases
by: E. V. Kovaleva, et al.
Published: (2021-01-01)

INTRAOPERATIVE PHOTODYNAMIC THERAPY FOR METASTATIC PERITONEAL TUMORS
by: E. A. Suleimanov, et al.
Published: (2016-09-01)

PHARMACOECONOMIC ANALYSIS OF THE USE OF OXALIPLATIN CHEMOTHERAPY FOR COLORECTAL CANCER.REAL (ACTUAL) CLINICAL PRACTICE DATA
by: A. V. Pavlysh, et al.
Published: (2015-03-01)

TO THE PROBLEM OF CHOICE OF THE TREATMENT TACTICS IN METASTATIC COLORECTAL CANCE
by: A. Z. Azanov, et al.
Published: (2016-04-01)

PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION
by: M. Yu. Frolov, et al.
Published: (2016-04-01)

Prognostic significance of neutrophil to lymphocyte ratio in patients with metastatic breast cancer on the background of eribulin therapy
by: A. V. Zyuzyukina, et al.
Published: (2022-09-01)